Roivant Sciences earnings date
Roivant Sciences (87S) Q2 2026 Earnings Report
DE:87S Q2 2026 EPS Results
- Actual EPS
- -EUR 0.24
- Consensus EPS
- -EUR 0.33
- Beat/Miss
- Beat by +EUR 0.09
- One Year Ago EPS
- -EUR 0.18
DE:87S Q2 2026 Revenue Results
- Actual Revenue
- EUR 31.86M
- Expected Revenue
- EUR 3.93M
- Beat/Miss
- Beat by +EUR 27.93M
- YoY Revenue Growth
- +2135.58%
Earnings Announcement Details
- Quarter
- Q2 2026
- Date
- 11/09/2026
- Time
- Before Open
- Conference Call
- Monday, November 9, 2026
Roivant Sciences's next earnings date is estimated for February 15, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
The call was strongly positive, driven by the successful LISRAYA launch, strong early commercial uptake, positive IMVT-1402 RA maintenance data, favorable brepo NIU results, compelling mosliciguat PH-ILD data, substantial liquidity, and an active 2027 pipeline. The company also acknowledged the failed CLE study, the likely discontinuation of Sjogren's development, ongoing FDA uncertainty for IMVT-1402, inventory timing effects, and a quarterly operating loss, but these issues were outweighed by the clinical and commercial progress discussed.
For LISRAYA, management expects “a modest headwind” from inventory dynamics in the December quarter and expects inventory stocking to be “completely irrelevant” as the company rounds the corner into next year; for IMVT-1402, it expects to return with an FDA and trial-plan update “probably later this year or early next year.” In 2027, Roivant expects to file the sNDA for NIU, “hopefully adding another indication in relatively short order” for brepo, and report top-line data for 1402 in Graves, as well as data in MG and “multiple program indication expansion.” The mosliciguat Phase III study is underway, actively screening and enrolling patients, with initiation of other trials in the coming months; the company is envisioning a broad program across PAH, IPF, PPF, and other forms of pulmonary hypertension, although it said some may be Phase III and some Phase IIs. Management said Graves enrollment has been strong and expects to provide an update on timing “relatively soon.”
- Strong Initial LISRAYA LaunchLISRAYA was approved in August and generated $31 million of net revenue during approximately 5 weeks on the market through September 30, reflecting strong initial demand, unmet medical need, and physician and patient enthusiasm. Hundreds of patients were on paid drug at quarter-end, many hundreds were on paid drug by the time of the call, and the company reported a broad initial prescriber base with early payer dynamics supporting good uptake.
- Broad LISRAYA Prescriber and Patient UptakeLISRAYA uptake included patients switching from off-label JAKs, IVIG, steroids, and immunosuppressants, as well as some newly diagnosed patients. The company reported many hundreds of prescribers and described the patient population as broad across practices.
- Positive Early LISRAYA Access DynamicsEarly payer coverage was described as straightforward, with very good conversion rates and no significant change in access relative to the beginning of the launch. The company stated that it is prepared to help patients obtain access despite varying levels of restrictions across plans.
- Positive IMVT-1402 Difficult-to-Treat RA Primary EndpointIn Period 2 of the randomized withdrawal RA study, approximately 92.5% of patients who continued on 600 milligrams maintained an ACR20 response at week 28, compared with approximately 75% on placebo. The study achieved a p-value for the 600-milligram arm, and the company said the data support deep therapeutic responses in patients who had failed multiple mechanisms and advanced therapies.
- IMVT-1402 Dose-Response and Deeper Clinical BenefitThe 300-milligram dose was not sufficient to preserve the response and looked similar to placebo, while 600 milligrams showed better performance across primary and secondary endpoints. At 600 milligrams, 80% of patients maintained an ACR50 response at week 28 versus 56% on placebo, with additional separation on ACR70 and continued improvement in ACR50 and ACR70 response rates over time.
- IMVT-1402 Activity in JAK-Experienced PatientsThe JAK-experienced subset performed about as well as the overall population, with preserved responses and positive ACR50 and ACR70 data despite prior failure of highly effective anti-inflammatory mechanisms.
- IMVT-1402 Safety Profile Remains FavorableSafety in the RA study was described as entirely consistent with prior disclosures, with event rates comparable with placebo, no new safety signals, and the drug continuing to look safe and well tolerated.
- Brepo NIU Data Support Potential New Standard of CareIn the CLARITY studies, placebo patients who failed therapy experienced median treatment failure at around 12 weeks, while median treatment failure was not observed in the brepo group over more than 48 weeks. The program met the primary and all secondary endpoints in both studies, with almost two-thirds of patients achieving steroid-free quiescence across subgroups; the company described the results as the largest benefit seen for a nonsteroidal therapy in NIU.
- Mosliciguat Demonstrates Strong PH-ILD EfficacyMosliciguat produced a 56% placebo-adjusted reduction in pulmonary vascular resistance at week 16 and a statistically significant 35-meter improvement in the key secondary six-minute walk endpoint. Week 24 exploratory analyses showed meaningful benefits in NT-proBNP and six-minute walk, while cardiac hemodynamic measures were described as strong.
- Mosliciguat Tolerability and Phase III ProgressIn the PH-ILD study, 98% of patients achieved the high dose, supporting a favorable safety and tolerability signal. Cough rates were lower than placebo, and the Phase III study was actively screening and enrolling patients.
- Expansion Plans for MosliciguatThe company is aggressively evaluating additional pulmonary hypertension and fibrotic lung disease opportunities, including PAH, IPF, and PPF. Management said it is envisioning a broad program and sprinting to start additional indications, with some potentially entering Phase II and others potentially entering Phase III.
- Strong Liquidity and Share RepurchasesCash was $4.2 billion as of September 30, partly reflecting receipts from the Moderna litigation. During the six months ended September 30, the company repurchased approximately $280 million of stock, representing approximately 9.4 million shares.
- Robust 2027 Pipeline OutlookManagement expects a busy 2027, including filing the sNDA for NIU, potentially adding another brepo indication, reporting important top-line data for IMVT-1402 in Graves' disease and data in myasthenia gravis, and pursuing multiple program and indication expansions. Enrollment in Graves' disease was described as strong.
DE:87S Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 15, 2027 | 2026 (Q3) | -0.27- | -0.15 | ― | ― |
| Nov 09, 2026 | 2026 (Q2) | -0.33-0.24 | -0.18 | -33.66% (-0.06) | |
| Aug 06, 2026 | 2026 (Q1) | -0.27-0.30 | -0.23 | -32.94% (-0.08) | |
| May 20, 2026 | 2025 (Q4) | -0.260.25 | -0.26 | 196.21% (+0.52) | |
| Feb 06, 2026 | 2025 (Q3) | -0.27-0.15 | 0.21 | -173.91% (-0.36) | |
| Nov 10, 2025 | 2025 (Q2) | -0.29-0.18 | -0.28 | 34.84% (+0.10) | |
| Aug 11, 2025 | 2025 (Q1) | -0.23-0.23 | 0.11 | -310.00% (-0.34) | |
| May 29, 2025 | 2024 (Q4) | -0.24-0.26 | -0.17 | -52.63% (-0.09) | |
| Feb 10, 2025 | 2024 (Q3) | -0.230.21 | 5.47 | -96.19% (-5.26) | |
| Nov 12, 2024 | 2024 (Q2) | -0.22-0.28 | -0.24 | -17.87% (-0.04) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
